Immunotherapy for Cancer in Kidney Transplant Patients: A Difficult Balance Between Risks and Benefits
Cancer is a major cause of morbidity and mortality in kidney transplant patients. Unfortunately, the use of new anti-cancer therapies such as immune checkpoint inhibitors (ICPIs) in this population has been associated with rejection rates up to 40%, in retrospective studies. The main challenge is to...
| Autors principals: | , , , , , |
|---|---|
| Format: | Article |
| Idioma: | English |
| Publicat: |
Frontiers Media S.A.
2024-11-01
|
| Col·lecció: | Transplant International |
| Matèries: | |
| Accés en línia: | https://www.frontierspartnerships.org/articles/10.3389/ti.2024.13204/full |